CareTrust REIT, Inc. (CTRE)

Theseus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Rental Revenue	246.41	228.26	198.6	187.51	190.2	173.61
Other Revenue	-	-	-	-	-	2.08
Total Revenue	329.84	296.29	217.77	196.13	192.35	178.33
Revenue Growth (YoY	43.26%	36.05%	11.03%	1.97%	7.86%	9.14%
Property Expenses	13.26	13.55	9.59	9.37	3.57	4.71
Selling, General & Administrative	31.11	28.92	21.81	20.17	26.87	16.3
Depreciation & Amortization	61.22	56.83	51.2	50.32	55.34	52.76
Provision for Loan Losses	-4.9	-4.9	-	-3.84	-	-
Total Operating Expenses	110.49	104.21	82.6	83.7	85.79	73.77
Operating Income	219.34	192.08	135.17	112.44	106.56	104.57
Interest Expense	-28.75	-30.31	-40.88	-30.01	-23.68	-23.66
Other Non-Operating Income	-2.21	-1.33	-	-	-	-
EBT Excluding Unusual Items	188.38	160.44	94.29	82.43	82.89	80.9
Gain (Loss) on Sale of Assets	1.66	-2.21	2.22	-3.77	-0.08	-0.04
Asset Writedown	-28.54	-33.18	-42.79	-86.16	-	-
Other Unusual Items	-0.66	-0.66	-	-	-10.83	-
Pretax Income	160.84	124.4	53.72	-7.51	71.98	80.87
Earnings From Continuing Operations	160.84	124.4	53.72	-7.51	71.98	80.87
Minority Interest in Earnings	1.29	0.68	0.01	-	-	-
Net Income	162.14	125.08	53.74	-7.51	71.98	80.87
Preferred Dividends & Other Adjustments	0.53	0.45	0.4	0.44	0.51	0.3
Net Income to Common	161.6	124.64	53.34	-7.95	71.48	80.57
Net Income Growth	156.32%	132.77%	-	-	-10.99%	74.44%
Basic Shares Outstanding	168	155	106	97	96	95
Diluted Shares Outstanding	169	155	106	97	96	95
Shares Change (YoY)	47.12%	46.17%	9.77%	0.64%	0.93%	2.27%
EPS (Basic)	0.96	0.81	0.50	-0.08	0.74	0.85
EPS (Diluted)	0.95	0.80	0.50	-0.08	0.74	0.85
EPS Growth	73.08%	60.00%	-	-	-12.56%	72.72%
Dividend Per Share	1.205	1.160	1.120	1.100	1.060	1.000
Dividend Growth	6.64%	3.57%	1.82%	3.77%	6.00%	11.11%
Operating Margin	66.50%	64.83%	62.07%	57.33%	55.40%	58.64%
Profit Margin	48.99%	42.07%	24.49%	-4.05%	37.16%	45.18%
EBITDA	277.44	246.13	186.05	162.81	161.96	157.38
EBITDA Margin	84.11%	83.07%	85.43%	83.01%	84.20%	88.25%
D&A For Ebitda	58.1	54.05	50.87	50.38	55.39	52.82
EBIT	219.34	192.08	135.17	112.44	106.56	104.57
EBIT Margin	66.50%	64.83%	62.07%	57.33%	55.40%	58.64%
Funds From Operations (FFO)	32.62	-	-	-	-	-
FFO Payout Ratio	582.62%	-	-	-	-	-
Revenue as Reported	329.84	296.29	217.77	196.13	192.35	178.33

Updated May 1, 2025. Source: S&P Global Market Intelligence. Real Estate template. Financial Sources.

SEC Filings: 10-K · 10-Q